Last reviewed · How we verify
NCT04135339
Efficacy of Exercise on Post Needling Soreness
NA trial testing Eccentric exercise in Post Needling Soreness in 69 participants. Completed in 1 September 2020.
31 October 2019
Quick facts
| Lead sponsor | University of Alcala |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 69 |
| Start date | 1 July 2019 |
| Primary completion | 31 October 2019 |
| Estimated completion | 1 September 2020 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Eccentric exercise
- Concentric exercise.
- Isometric exercise.
Conditions studied
- Post Needling Soreness — all drugs for Post Needling Soreness →
- Myofascial Pain — all drugs for Myofascial Pain →
- Myofascial Pain Syndrome — all drugs for Myofascial Pain Syndrome →
- Myofascial Trigger Point Pain — all drugs for Myofascial Trigger Point Pain →
Sponsor
University of Alcala
Who can join
18 and older, any sex, with Post Needling Soreness or Myofascial Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Introduction. The myofascial trigger point (MTrP) is a clinical entity related to different clinical pictures of pain. Dry needling (DN) would be the most appropriate therapeutic option for its treatment, although it has mild-moderate adverse effects, such as post-needling soreness (PNS). The exercise could be a strategy for its management, but no recommendations on the most effective mode have been found. Objectives 1. To determine the effectiveness of the exercise, differentiated according to the dominant mode (concentric, eccentric, isometric), in order to reduce the PNS of latent MTrPs. 2. To analyse the variables that, a priori, can influence the evolution of pain. Methods. Study design .A randomized clinical trial. Scenario Private or home-based consultation in Global Physiotherapy, Madrid, Spain. Participants. Voluntaries, with no symptoms in the triceps surae muscle,\>18 years old, who present at least one latent MTrP in medial gastrocnemius. Subjects with: other pathologies of lower limbs, active MTrP in the medial gastrocnemius muscle, contraindications to DN, prior application of DN and/or other therapies in MTrPs during the three months previous to the study (in gastrocnemius muscles) will be excluded. Intervention After DN of the medial gastrocnemius muscle, participants will be randomly allocated to four groups (three experimental groups and one control). In the experimental groups, subjects will be instructed to perform exercise protocols, differentiated according to the dominant contraction (concentric, eccentric, isometric) in muscle the gastrocnemius previously treated. Outcome measures. Pain intensity, by analog visual scale (VAS). Pressure pain threshold (PPT), by analog algometer. Demographics and anthropometrics. Protocol. Before and immediately after DN, the PPT will be evaluated in the latent MTrP. Pain intensity will also be assessed using VAS at two times: the first referred to pain during DN and the other referred to PNS two minutes after DN. The subjects will then be randomly divided into: a control group without any intervention after DN, and three experimental groups with different exercise protocols (differentiated by the dominant contraction: 3 sets x 15 reps, 3s each contraction, 30s of rest between sets) . The pain intensity will be recorded again by VAS, after the exercise session and at 6h, 12h, 24h, 48h, 72h after DN. PPT will also be assessed 2min after DN, after the exercise session and at 24h, and 48h after DN.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy of Exercise on Postneedling Soreness: A Randomized Controlled Trial.
Diciolla NS, Pérez-Clemente C, Cámara-Caballero M, Matienzo-Barreto A, et al · · 2021 · cited 4× · PMID 34884230 · DOI 10.3390/jcm10235527
Verify or expand the search:
- PubMed search for NCT04135339
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Eccentric exercise
Trials testing the same drug.
- NCT06391957 — Spirulina Supplementation In Recovery From Damaging Exercise · NA · recruiting
- NCT05316961 — Clinical Effectiveness of PEMF as a Treatment Adjunct to Eccentric Exercise for Achilles Tendinopathy · NA · unknown
- NCT04600050 — Eccentric Contraction-based Resistance Exercise for Chronic Stroke Patients · NA · unknown
- NCT04042012 — Percutaneous Needle Electrolysis (PNE) in Soleus Injury · NA · completed
- NCT03559452 — Muscle Damage and Disuse Atrophy · NA · completed
Other University of Alcala trials
Trials by the same sponsor.
- NCT06599164 — Evaluation of Vastus Medialis Muscle Inhibition in Indoor Soccer Players With and Without ACL Injury · not yet recruiting
- NCT06587412 — Treatment of Lateral Epicondylalgia With Shock Waves · NA · recruiting
- NCT07333443 — Caffeine and Sport Climbing Performance · NA · completed
- NCT07015008 — Sleep and Maximal Fat Oxidation · NA · completed
- NCT06723821 — Noninvasive Neuromodulation in the Management of Post-COVID Musculoskeletal Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04135339 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alcala
- Last refreshed: 12 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04135339.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing